Dr Mark, Scientific Co-Founder of Voltron Therapeutics, Inc.

NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) – Voltron Therapeutics, Inc. today announced that the guest essay by the company’s scientific co-founder, Dr. Mark C. Poznansky, titled “The vaccines we have are good . But they could be so much better, ”was published in The New York Times on June 10, 2021.

Dr. Mark C. Poznansky is Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr Poznansky is also the Scientific Founder of Voltron Therapeutics, helping to advise on early clinical research and test implementation in the clinical setting, among others.

In the trial, Dr Poznansky and his colleague Dr Michael V. Callahan discuss the impressive and continued efforts to disseminate a safe and effective vaccine on a large scale in the population, as well as the remaining need for new vaccines that address to the evolution of variants that can overcome the immunity provided by existing COVID-19 vaccines and / or previous infections.

As the scientific co-founder of Voltron Therapeutics, Dr. Poznansky was instrumental in the development of HaloVax ™, a self-assembly (SAV) vaccine against COVID-19. HaloVax can not only prevent disease, but can also offer safe delivery with a strong and broad immune response, specially designed to be applicable to emerging viral targets, such as COVID-19 and its variants. Above all, HaloVax ™ is designed with safety as a top priority to avoid known side effects of vaccines, including an excessive local response or an inappropriate immune response. Other vaccine approaches, in many cases, simply trick the immune system to target one aspect of the COVID-19 virus, namely the spike protein, and only as it appeared during the original pandemic outbreak in 2019. HaloVax is a flexible system for a wide range of immune responses against a virus – simultaneously training the immune system to target several proteins contained in the virus that can be easily modified to quickly attack new evolving variants. The need for second-generation vaccine platforms like HaloVax is growing, given the rise of the Delta variant and the inevitable increase in new variants that evolve to evade first-generation vaccines.

The vaccine is constructed on the basis of a heat shock protein (HSP70) -avidin fusion protein which activates the cellular component of the immune system; this is different from most other vaccination efforts, which have used adjuvants such as alum. The second part of the vaccine consists of virus targeting peptides derived from our understanding of the structure of COVID-19, which are linked to the heat shock protein via biotin. This allows for rapid iteration and up-to-date, informed modifications of data in peptide sequences to enable rapid production and adapt to potential changes in the pathogen itself. The selected immunogenic peptides complement the personalized COVID-19 vaccine.

Voltron Therapeutics previously announced positive data from its second round of preclinical animal testing of its COVID-19 vaccine. This study examined an updated peptide construct, based on initial testing as well as recent scientific developments, to identify the best balance of immune responses for the prevention of this pandemic pathogen.

The study consisted of a complete preclinical study in mice, close to GLP, evaluating whether the self-assembling vaccine, composed of the immune activating component MTBhsp70-Avidin and the antigen targeting biotinylated immunogenic peptides, increased the response immune compared to controls or peptides alone.

The results demonstrated that the self-assembling vaccine construction did significantly increase the responses of helper and cytotoxic T lymphocytes to vaccine-targeted antigens compared to controls. This proof of concept for the after-sales service platform is essential to the COVID-19 program, additional infectious disease targets as well as oncology applications of this cutting-edge technology. HaloVax is developed in collaboration with Hoth Therapeutics, Inc (NASDAQ: HOTH).

“We remain optimistic that our recent successful preclinical tests will quickly lead to clinical trials in humans and bring us one step closer to a safe, broad-acting, effective and long-lasting vaccine to help prevent disease caused by COVID-19 and its future variants. Our discovery and operations teams have placed us at the forefront of vaccine development, leveraging our platform technology to create vaccines in a more rapid and adaptable manner, ”said Pat Gallagher, CEO of Voltron Therapeutics, Inc.

About Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc., a Delaware company, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital’s new vaccine self-assembly technology in various indications, particularly in oncology and emerging infectious diseases. Voltron holds an exclusive worldwide license for this technology. Thanks to the work of our team of world-class researchers and physicians, this technology has demonstrated in certain preclinical studies a first proof of concept in two infectious diseases (Lassa fever and Q fever) as well as two indications in oncology (cancers of the lassa fever). ovary and HPV). For more information, please visit www.voluntex.com.

About HaloVax ™, LLC

HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ: HOTH) HaloVax’s mission is to develop a new self-assembly vaccine against COVID-19, using technology licensed by Voltron Therapeutics, Inc. of the Vaccine and Immunotherapy Center at Massachusetts General Hospital. The vaccine is designed from a platform validated to provide personalized T cell immunity against COVID-19, as well as being able to adapt quickly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients with indications such as atopic dermatitis, chronic wounds, psoriasis, asthma and acne. For more information, please visit www.hoththerapeutics.com.

Forward-looking statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release include, without limitation, statements relating to the advancement and development by VaxCelerate. Platform, the start of clinical trials, the availability of clinical trial data and other information that is not historical information. When used herein, words such as “anticipate”, “be”, “will”, “plan”, “could”, “continue” and similar expressions are intended to identify forward-looking statements. In addition, any statement or information that refers to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, is forward-looking. All forward-looking statements are based on Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for his expectations and beliefs, but they are inherently uncertain. Voltron may not achieve his expectations, and his beliefs may not turn out to be correct. Actual results could differ materially from those described or suggested by these forward-looking statements due to various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Therefore, forward-looking statements should be considered only as Voltron’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, activity levels, performance or achievements. Voltron does not undertake and specifically disclaims any obligation to update, republish or revise any forward-looking statement to reflect new information, future events or circumstances or to reflect the occurrence of unforeseen events, except as required by law. required.

Investor contacts:

Matt duffy
President
Voltron Therapeutics, Inc.
646-335-5923
[email protected]

Jason assad
Voltron Therapeutics, Inc.
Investor Relations
678-570-6791
[email protected]


Source link

Comments are closed.